Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China’s National Medical Products Administration (NMPA) has approved sosimerasib, a Category 1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non‑small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS‑driven cancers, a historically “undruggable” oncogene.
KRAS “Undruggable” Target Cracked: Sosimerasib joins sotorasib (Amgen) and adagrasib (Mirati/BMS) as approved KRAS G12C inhibitors, validating direct KRAS targeting as a viable therapeutic strategy.
China Market First: As a domestically developed Category 1 drug, sosimerasib may secure formulary preference and reimbursement advantages vs. imported competitors in China’s healthcare procurement system.
Adherence Optimization: The “two tablets once daily” dosing simplifies administration vs. some competitor regimens, potentially improving patient compliance and real‑world effectiveness.
Pipeline Expansion:FAK inhibitor combination development for first‑line therapy addresses single‑agent resistance mechanisms, positioning Hangyu Pharma for label expansion and earlier‑stage market entry.
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch timelines, market share capture, and FAK combination development outcomes. Actual results may differ due to risks including competitive pricing pressure, reimbursement negotiation delays, and combination trial enrollment challenges.-Fineline Info & Tech
By Fineline Cube 